Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 4/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652927 | 0.83 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL2645542 | 0.79 | GCK (0.33) | PIK3CDPIK3CAPIK3CBPIK3CGL3MBTL1 | |
| SCHEMBL2645256 | 0.79 | TSHR (0.33) | PIK3CDPIK3CAPIK3CBPIK3CGL3MBTL1 | |
| SCHEMBL15228357 | 0.68 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGEPAS1 | |
| SCHEMBL2646076 | 0.68 | CYP19A1 (0.41) | GRIA4 | |
| SCHEMBL1263198 | 0.66 | CCR2 (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGEPAS1 | |
| SCHEMBL2073371 | 0.66 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGCTSC | |
| SCHEMBL29212553 | 0.66 | EPAS1 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGEPAS1 | |
| SCHEMBL16034697 | 0.66 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGEPAS1 | |
| SCHEMBL19682382 | 0.65 | TRPV4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-15 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | PIK3CD 2211/4885PIK3CA 1981/4885PIK3CB 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.